Rituximab

...follicular, CD20-positive, B-cell NHL as a single agent. It was approved in the European Union under the trade name MabThera® in June 1998. Rituxan is also approved for the treatment of NHL for the following: - Previously untreated...

In this article: Rituxan, FDA, CD20, Biogen Idec, Genentech, NHL, Leukemia, Nausea, and Medical advice

* Roche unit Genentech and Biogen Idec <BIIB.O> received a complete response from America's Food and Drug Administration (FDA) for Rituxan for chronic lymphocytic leukemia on Wednesday and said they would continue final label discussions with...

In this article: Food and Drug Administration, Adecco S.A., Genentech, Novartis, Revenue, Asthma, Rituxan, Xolair, and Swiss International Airlines

...Genentech Inc. and partner Biogen Idec Inc. said Wednesday the Food and Drug Administration is withholding a decision to expand approval of Rituxan as a leukemia treatment, pending further discussion. Neither company disclosed the specific...

In this article: Food and Drug Administration, Genentech, Biogen, Rituxan, Leukemia, Cancer, Rheumatoid arthritis, Cambridge, and NEW YORK

The most common treatment for the disease is a regimen of chemotherapy combined with Roche and Biogen's targeted antibody drug rituximab (Rituxan), which kills excess B-cells of the immune system. "Even when a cure is not possible, treatment...

In this article: Paul Allen, Cancer, E mail, Seattle, and Diffuse large B-cell lymphoma

...for TRU-015, a product designed by Trubion scientists to have the same targeting capability of Roche and Biogen Idec's rituximab (Rituxan) against inflammatory cells with a marker called CD20. But because the Trubion drug is a smaller...

In this article: Wyeth, Pfizer, Rheumatoid arthritis, Nasdaq, and Seattle

...that both FcGR-2A and FcGR-3A receptors dictate the therapeutic response rate of B-cell non-Hodgkin's lymphoma (B-NHL) patients to rituximab treatment. This was based on a well defined, retrospective analysis of patient samples from B-NHL...

In this article: Cancer, Antibody, Breast cancer, Trastuzumab, NHL, Targeted therapy, and Cetuximab

...in Genmab -- which is developing cancer drug Arzerra with pharma major GlaxoSmithKline, a rival to Swiss Roche and U.S. Biogen Idec's Rituxan -- slid 12.2 percent to end at 100.50 crowns before the report. The MSCI European pharma, biotech...

In this article: Genmab, Revenue, GlaxoSmithKline, Tax, Cancer, Rituxan, Handelsbanken, Danske Bank, Credit Suisse, and UBS

Genmab A/S (Copenhagen:GEN) announced today the initiation of a Phase III study of Arzerra (TM) ofatumumab plus chemotherapy versus rituximab plus chemotherapy to treat patients with relapsed or refractory diffuse large B-cell lymphoma...

In this article: Genmab, Ofatumumab, Trademark, GlaxoSmithKline, Cancer, and B-cell lymphoma

...dry eyes, and, in severe cases, loss of vision. Women are more likely than men to develop the disease. The study suggests that drug rituximab is a potentially effective new treatment for the most severe forms of Graves' eye disease.

In this article: Inflammation, Steroid, Arthritis, Ophthalmology, Surgery, Oculoplastics, and Autoimmune disease

...with severe Graves' eye disease experienced rapid improvement of their symptoms and improved vision following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced.

In this article: Inflammation, Ophthalmology, Steroid, University of California at Los Angeles, Surgery, Oculoplastics, and B-cell lymphoma